S
Stephen Price
Researcher at Genentech
Publications - 29
Citations - 534
Stephen Price is an academic researcher from Genentech. The author has contributed to research in topics: In vivo & Kinase. The author has an hindex of 13, co-authored 29 publications receiving 519 citations. Previous affiliations of Stephen Price include Janssen Pharmaceutica & Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Nguyen Tan,Maureen Wong,Michelle Nannini,Rebecca Hong,Leslie Lee,Stephen Price,Karen Williams,Savy Pascal Pierre,Peng Yue,Deepak Sampath,Jeffrey Settleman,Wayne J. Fairbrother,Lisa D. Belmont +12 more
TL;DR: The efficacy of agents that target the MAPK and PI3K pathways can be improved by combination with a Bcl-2 family inhibitor, and the G-963/navitoclax combination was more effective than either single agent in the KRAS mutant H2122 xenograft model.
Journal ArticleDOI
Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta
Jeremy Murray,Zachary Kevin Sweeney,Bryan K. Chan,Mercedesz Balazs,Erin K. Bradley,Georgette Castanedo,Christine Chabot,David Chantry,Michael Flagella,David Michael Goldstein,Rama K. Kondru,John Lesnick,Jun Li,Matthew C. Lucas,Jim Nonomiya,Jodie Pang,Stephen Price,Laurent Salphati,Brian Safina,Pascal Savy,Eileen Mary Seward,Mark Ultsch,Daniel P. Sutherlin +22 more
TL;DR: A series of potent and selective benzimidazole-based inhibitors of PI3Kδ are identified using a structure-based design approach and the pharmacokinetic properties and the ability of compound 5 to inhibit the function of B-cells in vivo are described.
Patent
Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
Archer Janet Ann,Bordogna Walter,Richard James Bull,David Edward Clark,Dyke Hazel Joan,Gill Matthew Iain Andrew,Neil Victor Harris,Heuvel Marco Van Den,Stephen Price +8 more
TL;DR: A compound of formula (I) which can be used in the treatment of diseases associated with histone deacetylase enzymatic activity was proposed in this article, where it was shown to be effective in treating cancer.
Patent
Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
Georgette Castanedo,Bryan K. Chan,David Michael Goldstein,Rama K. Kondru,Matthew C. Lucas,Wylie Solang Palmer,Stephen Price,Brian Safina,Pascal Pierre Savy,Eileen Mary Seward,Daniel P. Sutherlin,Zachary Kevin Sweeney +11 more
TL;DR: Formula I (Ia and Ib) compounds are useful for inhibiting the delta isoform of PBK, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer as mentioned in this paper.
Patent
8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
TL;DR: In this paper, the imidazopyridines of formula I with anti-cancer and/or anti- inflammatory activity were used for in vitro, in situ and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.